# Cadence Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cadence-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: Seattle, US
- Website: www.cadencebiomedical.com
- Total disclosed funding: $3M
- Latest round: Series B (Jun 25, 2015)
- Investors on record: 9

## About

Cadence Biomedical, Inc. specializes in innovative rehabilitation technology, specifically a wearable device that assists individuals with mobility recovery after neurological impairments like stroke and spinal cord injury.Cadence Biomedical focuses on creating solutions for individuals recovering from neurological impairments. Established in Seattle, US, the company has developed a unique product called Kickstart. The company had a key funding event on June 25, 2015, when HealthTech Capital led a Series B financing round of USD 1.2 million, with investors including BioPacific Partners and Frontier Angel Fund. The total amount raised by the company amounts to USD 1.2 million.Cadence Biomedical offers Kickstart, a wearable walking device designed to aid users in regaining walking ability after neurological impairments. Utilizing proprietary Exotendon technology, the device stabilizes hips and legs while assisting in step motion, facilitating the relearning of natural walking patterns. It is utilized by individuals in rehabilitation and healthcare professionals across various international markets, particularly in the US and select European regions, often supported by insurance coverage.Revenue for Kickstart is generated through direct sales to consumers and rehabilitation centers, frequently facilitated by insurance reimbursements. The sales framework includes direct-to-consumer transactions and partnerships with healthcare providers, allowing clients to acquire the device through healthcare facilities or directly from Cadence Biomedical, with potential payment plans based on insurance coverage.Cadence Biomedical is set to further its development efforts with new product launches planned for the near future, though specific details and release dates are not available. The company aims to expand into additional markets, targeting regions beyond the US and select European countries. The recent Series B financing round of USD 1.2 million will support these initiatives, enhancing the company's capabilities in product development and market reach.

## Funding rounds

- Series B, Jun 25, 2015, $1.2M — HealthTech Capital, Frontier Angel Fund, BioPacific Partners
- Series A, Apr 26, 2012, $1.1M — Keiretsu Forum, Alliance of Angels, Tech Coast Angels, Sand Hill Angels, HealthTech Capital, Washington Medical Technology Angel Network
- Series A, Jan 20, 2012, $0.8M — Keiretsu Forum, Alliance of Angels, Wings Capital, Sand Hill Angels, HealthTech Capital, Frontier Angel Fund

## Investors

- Keiretsu Forum — Series A
- Alliance of Angels (https://capitalatlas.ai/funds/alliance-of-angels) — Series A
- Wings Capital (https://capitalatlas.ai/funds/wings-capital) — Series A
- Sand Hill Angels (https://capitalatlas.ai/funds/sand-hill-angels) — Series A
- HealthTech Capital — Series A, Series B
- Frontier Angel Fund (https://capitalatlas.ai/funds/frontier-angel-fund) — Series A, Series B
- Tech Coast Angels — Series A
- Washington Medical Technology Angel Network — Series A
- BioPacific Partners (https://capitalatlas.ai/funds/biopacific-partners) — Series B